Senior Clinical Trial Manager / Associate Director
Abata TherapeuticsFull Time
Mid-level (3 to 4 years), Senior (5 to 8 years)
Watertown, Massachusetts, United States
Key technologies and capabilities for this role
Common questions about this position
Candidates should be pursuing a B.S. or B.A. in Biology or a Health sciences field, or similar, with excellent analytical and written and oral communication skills, ability to work independently and as part of a team, and comfort with basic statistical concepts.
The team is a tight knit, closely collaborative, highly creative group working to make the promise of Prime Editing a reality for patients with severe genetic diseases.
This information is not specified in the job description.
Prime Medicine offers full reimbursement for monthly commuting costs including MBTA, Commuter Rail, or Bluebikes, participation in regular seminars with industry experts, and full participation in employee activities including learning and development. A cutting-edge team provides mentorship and networking opportunities.
A strong candidate is highly motivated, organized, and collegial, with experience in Biology and/or Health-related sciences, ready to assist in operationalizing clinical trials for gene therapy.
Gene editing technology for genetic diseases
Prime Medicine focuses on gene editing, specifically using a technology called Prime Editing to make precise changes to DNA. This technology can identify and fix faulty DNA segments, which helps restore normal genetic function. The company aims to cure, halt, or prevent genetic diseases, providing long-term benefits to patients. Prime Medicine targets individuals with genetic disorders, a significant market globally. Unlike many competitors, it emphasizes collaboration with research institutions and pharmaceutical companies to advance its technology and bring it to market through licensing agreements and partnerships. The leadership team has extensive experience in developing innovative medicines, and the company is committed to enhancing its technological capabilities.